Kwong Mona, Wasan Kishor M
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
Pharm Res. 2003 Jul;20(7):1009-14. doi: 10.1023/a:1024454105124.
The objective of this study was to determine if cyclosporine (CSA) binds directly to the neutral lipid-binding site of lipid transfer protein I (LTP I).
This was accomplished by determining LTP I concentrations and cholesteryl esters (CE) and CSA radioactivity of eluted fast protein liquid chromatography (FPLC) fractions following an injection of different treatment groups (i.e., LTP I alone, 3H-CE liposomes alone, 3H-CSA liposomes alone, 3H-CE liposomes + LTP I, and 3H-CSA liposomes + LTP I) onto an FPLC column. Our hypothesis is that CSA will bind to the neutral lipid-binding site of LTP I because of its high solubility/interaction with cholesterol and triglycerides.
Coincubation of LTP I with 3H-CE liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and the appearance of a broad LTP I peak at fractions 30-34 compared to control. Coincubation of LTP I with 3H-CSA liposomes resulted in a significant decrease in the LTP I peak reported at fraction 10 and fraction 30 compared to control. In addition, 30% of the original radioactivity associated with 3H-CSA liposomes was found coeluted with the unbound LTP I peak at fraction 10. Taken together, these findings suggest that CSA does bind to the neutral lipid-binding site of LTP I but may also bind to other regions along the LTP I molecule.
We have determined that LTP I mediated transfer of CSA between lipoproteins may be a result of the direct binding of CSA to LTP I at both its neutral binding site and potentially other binding sites along the molecule. These findings provide further evidence that the distribution/redistribution of drugs among plasma lipoproteins facilitated by LTP I may serve as a possible mechanism for determining the ultimate fate of drug compounds.
本研究的目的是确定环孢素(CSA)是否直接结合至脂质转运蛋白I(LTP I)的中性脂质结合位点。
通过测定不同处理组(即单独的LTP I、单独的3H-胆固醇酯(CE)脂质体、单独的3H-CSA脂质体、3H-CE脂质体+LTP I以及3H-CSA脂质体+LTP I)注射到快速蛋白质液相色谱(FPLC)柱上后洗脱的FPLC组分中的LTP I浓度、胆固醇酯(CE)和CSA放射性来实现。我们的假设是,CSA将结合至LTP I的中性脂质结合位点,因为它与胆固醇和甘油三酯具有高溶解性/相互作用。
与对照组相比,LTP I与3H-CE脂质体共孵育导致第10组分处报道的LTP I峰显著降低,并且在第30 - 34组分处出现一个宽的LTP I峰。与对照组相比,LTP I与3H-CSA脂质体共孵育导致第10组分和第30组分处报道的LTP I峰显著降低。此外,在第10组分处发现与3H-CSA脂质体相关的原始放射性的30%与未结合的LTP I峰共洗脱。综上所述,这些发现表明CSA确实结合至LTP I的中性脂质结合位点,但也可能结合至LTP I分子上的其他区域。
我们已经确定LTP I介导的CSA在脂蛋白之间的转运可能是CSA在其中性结合位点以及可能沿分子的其他结合位点直接结合至LTP I的结果。这些发现提供了进一步的证据,即由LTP I促进的药物在血浆脂蛋白之间的分布/重新分布可能作为确定药物化合物最终命运的一种可能机制。